Compare Okta, Inc. (OKTA) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Okta, Inc. trades at $172.7 (market cap $29.30B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Okta, Inc. is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.02% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| OKTA | ZBH | |
|---|---|---|
Market Cap | $29.30B | $17.97B |
Sector | Technology | Health |
52-Week High | $173.04 | $104.26 |
52-Week Low | $62.93 | $79.58 |
Enterprise Value | $27.05B | $25.04B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $167.60, down 1.76% on the day but up 94% year-to-date, driven by strong earnings beats and AI-driven demand for cybersecurity. The stock is in a bullish technical trend with support at $166 and resistance at $170. Fundamentals show improving profitability, with Q2 2026 EPS of $1.05 beating estimates, revenue growth accelerating to $2.61 billion in 2025, and a net income margin turning positive to 9.63% in 2026 projections. Analyst sentiment remains overwhelmingly positive with a $181.61 consensus target.
The outlook for OKTA is bullish, supported by robust earnings momentum, AI security adoption, and strong institutional backing. Key opportunities include expanding AI-agent security offerings and sustained revenue growth. Risks involve intense competition from CrowdStrike and Microsoft, high valuation multiples, and insider selling activity. The stock's proximity to its 52-week high suggests cautious entry points may be warranted despite positive catalysts.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
